Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572

Watchlist Manager
Zhejiang CONBA Pharmaceutical Co Ltd Logo
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Watchlist
Price: 4.68 CNY -2.09% Market Closed
Market Cap: 11.7B CNY
Have any thoughts about
Zhejiang CONBA Pharmaceutical Co Ltd?
Write Note

Net Margin
Zhejiang CONBA Pharmaceutical Co Ltd

7.5%
Current
14%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
7.5%
=
Net Income
486.8m
/
Revenue
6.5B

Net Margin Across Competitors

Country CN
Market Cap 11.8B CNY
Net Margin
8%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 741.7B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.8T DKK
Net Margin
35%
Country US
Market Cap 346.4B USD
Net Margin
17%
Country US
Market Cap 250B USD
Net Margin
19%
Country CH
Market Cap 199.8B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.7B CHF
Net Margin
35%
Country US
Market Cap 148.7B USD
Net Margin
7%
No Stocks Found

Zhejiang CONBA Pharmaceutical Co Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.

Intrinsic Value
8.12 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
7.5%
=
Net Income
486.8m
/
Revenue
6.5B
What is the Net Margin of Zhejiang CONBA Pharmaceutical Co Ltd?

Based on Zhejiang CONBA Pharmaceutical Co Ltd's most recent financial statements, the company has Net Margin of 7.5%.